Team:Westminster/Project

From 2012.igem.org

(Difference between revisions)
(Prototype team page)
(Overall project)
Line 35: Line 35:
== '''Overall project''' ==
== '''Overall project''' ==
-
Tell us more about your project.  Give us background.  Use this is the abstract of your project. Be descriptive but concise (1-2 paragraphs)
+
Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSCs) are able to drive the growth of the tumor. CSCs also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
 +
The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We aim to characterise the promoters for a range of ALDH isoforms and combine synthetic biology and fluorescence techniques to identify and eliminate these cells, offering a novel tool for cancer diagnosis and treatment.
== Project Details==
== Project Details==

Revision as of 08:23, 16 July 2012


This is a template page. READ THESE INSTRUCTIONS.
You are provided with this team page template with which to start the iGEM season. You may choose to personalize it to fit your team but keep the same "look." Or you may choose to take your team wiki to a different level and design your own wiki. You can find some examples HERE.
You MUST have all of the pages listed in the menu below with the names specified. PLEASE keep all of your pages within your teams namespace.


Home Team Official Team Profile Project Parts Submitted to the Registry Modeling Notebook Safety Attributions



Contents

Overall project

Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSCs) are able to drive the growth of the tumor. CSCs also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.

The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We aim to characterise the promoters for a range of ALDH isoforms and combine synthetic biology and fluorescence techniques to identify and eliminate these cells, offering a novel tool for cancer diagnosis and treatment.

Project Details

Part 2

The Experiments

Part 3

Results